Enseval Putera Megatrading Tbk PT operates in the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Enseval Putera Megatrading Tbk PT with three other
drug stores in Asia:
Cachet Pharmaceutical Company., Limited
sales of 8.20 billion Chinese Renmimbi [US$1.25 billion]
of which 100%
Shandong Realcan Pharmaceutical Co Ltd
(9.75 billion Chinese Renmimbi [US$1.49 billion]
of which 100%
was Medical Devices Sales), and
Hokuyaku Takeyama Holdings, Inc
based in Japan
(212.11 billion Japanese Yen [US$1.92 billion]
of which 72%
was Pharmaceutical Business).
Enseval Putera Megatrading Tbk PT reported sales of 17.47 trillion Indonesian Rupiahs (US$1.28 billion)
December of 2015.
increase of 2.7%
versus 2014, when the company's sales were 17.01 trillion Indonesian Rupiahs.
Sales at Enseval Putera Megatrading Tbk PT have increased during each of the previous five years
(and since 2010, sales have increased a total of 80%).
Sales of Other saw an increase
that was more than double the company's growth rate: sales were up
16.5% in 2015, from
2.12 trillion Indonesian Rupiahs to 2.47 trillion Indonesian Rupiahs.
Not all segments of Enseval Putera Megatrading Tbk PT experienced an increase in sales in 2015:
sales of Consumer Products fell 0.2% to 7.52 trillion Indonesian Rupiahs.